相关实验视频

Updated: Jan 12, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

在Rhabdomyosarcoma中,PRKG1阻碍了肌原分化,并预测了对AKT抑制剂ipatasertib的反应

Estela Prada¹, Pablo Táboas¹, Evelyn Andrades²

¹SJD Pediatric Cancer Center Barcelona, Institut de Recerca Sant Joan de Déu (IRSJD). Esplugues de Llobregat, Barcelona, Spain.

Nature communications

|November 6, 2025

概括

伊帕塔塞尔蒂布通过向蛋白质激酶PRKG1来显示在拉布多米索尔科马 (RMS) 中的抗瘤活性. PRKG1表达可以预测患者对Ipatasertib治疗的反应,为RMS治疗提供了一个新的生物标志物.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

拉布多米索尔科马 (RMS) 显示阻断了肌体发生和激活了AKT/mTOR通路,但直接抑制的有效性有限.
全AKT抑制剂Ipatasertib和Miransertib在RMS模型中进行了活性评估.

研究的目的:

评估Ipatasertib和Miransertib在RMS细胞系和患者衍生异种移植 (PDX) 的疗效.
调查PRKG1在RMS进展和对治疗的反应中的作用,这是AKT与Ipatasertib的共同目标.

主要方法:

在RMS细胞系和PDX模型中对Ipatasertib和Miransertib的评估.
对PRKG1-贫乏的RMS细胞和异种移植的转录基因分析.
对PRKG1表达与临床和分子特征的相关性分析.

主要成果:

与Miransertib不同的是,Ipatasertib在RMS的一个子集中表现出显著的抗瘤活性.
抑制PRKG1减少了瘤的形成,并诱导了肌原分化.
在RMS中增加的PRKG1表达与中皮特征和增强的Ipatasertib敏感性相关.

结论:

PRKG1在RMS肌形成和瘤进展中发挥作用.
PRKG1是预测Ipatasertib在RMS中的疗效的潜在临床生物标志物.
伊帕塔塞尔蒂布表现出剂量依赖的抗瘤活性,在每天25毫克/公斤时有效.

更多相关视频

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

相关概念视频

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...